The diagnostics group Novacyt announced on Monday that it had delisted the British company Yourgene Health, whose acquisition it recently completed, this morning.

Following an application to the London Stock Exchange, the listing of Yourgene shares on the London Stock Exchange was cancelled this Monday, with effect from 7:00 am.

The £16.7 million (approx. €19.5 million) acquisition of Yourgene Health, a British specialist in molecular diagnostics, should enable Novacyt to diversify, notably into non-invasive prenatal screening devices, for Down syndrome (trisomy 21) for example.

Copyright (c) 2023 CercleFinance.com. All rights reserved.